19 results about "Cerebral damage" patented technology

The present invention relates to a pharmaceutical composition comprising a pharmaceutically acceptable vehicle and non-pungent derivatives of capsaicin, in their tautomeric forms and pharmaceutically acceptable salts, as the sole active ingredient, for use in the stimulation of the sphenopalatine ganglion and the enhancement of cerebral blood flow, to prevent or reduce brain injury resulting from decreased cerebral blood flow. The composition is administered via the oral transmucosal route, preferably in the form of a mucoadhesive tablet, and may be formulated for immediate or prolonged release, ensuring effective and tolerable absorption while avoiding the irritant effects associated with pungent capsaicin.

This invention relates to pharmaceutical compositions, including compositions adapted for intranasal administration, comprising an active ingredient, including dexmedetomidine, pomalidomide, a selective phosphodiesterase type 4 inhibitor such as roflumilast, or combinations thereof, useful in the treatment of traumatic brain injury (TBI), including to prevent or reduce the neurological sequalae of TBI.

This invention relates to animal models and their applications, specifically to a method for constructing a spontaneous mouse cerebral edema model and its application. This invention utilizes PEN2... fl / + Mice and PEN2 fl / + Mice were mated to obtain PEN2. fl / fl Homozygous mice; then the obtained PEN2 fl / fl Mice and hGFAP Cre / + Mice were mated to obtain PEN2. fl / + hGFAP Cre / + Mice; the final PEN2 obtained fl / + hGFAP Cre / + Mice and PEN2 fl / fl Mice were mated to obtain PEN2. fl / fl hGFAP Cre / + The mouse model is a spontaneous mouse cerebral edema model. In this model, PEN2 protein levels are significantly downregulated, and the mouse exhibits a severe cerebral edema phenotype. This model can be used to establish a cerebral edema drug screening platform. It can also be used for research on cerebral edema-related diseases, such as the pathogenesis of cerebral edema caused by infection, glioma, and traumatic brain injury, as well as for the development of technologies and products for the diagnosis and treatment of related diseases.

The application discloses application of a MAC-1 agonist in preparation of a medicine for treating and / or relieving cerebral hemorrhage. Specifically disclosed is the use of Leukadherin-1 (LA-1) or a pharmaceutically acceptable salt, isomer or derivative thereof in preparation of a medicine for treating cerebral hemorrhage and secondary brain injury thereof. The medicine can inhibit the migration of immune cells across the blood-brain barrier, reduce cerebral edema, promote hematoma absorption and reduce neural inflammation by regulating the MAC-1-mediated immune adhesion signal pathway, thereby exerting a neuroprotective effect. Meanwhile, a pharmaceutical composition containing the MAC-1 agonist is provided. The application provides a new target and a drug development strategy for cerebral hemorrhage treatment.

Described are methods and systems for transcervical access of the cerebral arterial vasculature and treatment of cerebral occlusions, including ischemic stroke. The methods and devices may include methods and devices which may provide aspiration and passive flow reversal, those which protect the cerebral penumbra during the procedure to minimize injury to brain, as well as distal catheters and devices to remove an occlusion. The methods and devices that provide passive flow reversal may also offer to the user a degree of flow control. Devices and methods which provide a way to securely close the access site in the carotid artery to avoid the potentially devastating consequences of a transcervical hematoma are also described.

The present disclosure relates to a mobile state electrode screening method, device, equipment and computer readable storage medium. Relates to the field of computer technology, including through the band-pass filter to the target electroencephalogram signal is accurate division get multiple preset frequency band, and combined with the relative power calculation realizes feature normalization, overcomes the defect that the traditional method is not enough to protect the subtle electroencephalogram feature. Secondly, based on the relative power data statistics index of normal user and abnormal user is calculated, and the variation coefficient double verification mechanism is introduced, when the statistical index is less than the first threshold value and the variation coefficient is less than the second threshold value, the target electrode is confirmed, this kind of comprehensive screening standard based on statistical significance and feature stability ensures that the electrode has both discriminant ability and robustness. Through this targeted screening mechanism, the electrode redundancy is significantly reduced, which can focus on the electrodes that are really effective for brain injury classification, so as to realize high-precision classification in mobile environment and optimize the calculation efficiency.

This invention discloses the application of induced pluripotent stem cell (EPC) derived from induced pluripotent stem cell differentiation in the preparation of stroke therapeutic agents. Through intravenous injection of EPCs into an animal model of stroke, this invention demonstrates that this method can treat stroke by inhibiting atherosclerosis, reducing cerebral infarction levels, promoting angiogenesis in lesioned brain tissue, improving inflammatory responses in lesioned brain tissue, and repairing nerve damage and brain injury. The above research results of this invention provide a new treatment method for stroke in clinical practice.

The present invention provides a central nervous system targeted pharmaceutical composition that can be used to treat various forms of brain damage, wherein an integrin antibody is attached to a transmembrane protein of an exosome through genetic engineering, and said exosome is used as a carrier to encapsulate a therapeutic drug.

This invention discloses an adaptive drug delivery system for ischemic stroke, its preparation method, and its application. MMP-2 responsive peptide-drug dimers are loaded onto the surface of mesoporous polydopamine for intervention or treatment of cerebral ischemia-reperfusion injury. The system allows for targeted drug delivery based on individual differences in disease progression among patients, precisely promoting brain injury repair. This invention applies MMP-2 responsive peptides to the treatment of ischemic stroke, using mesoporous polydopamine as a drug carrier, providing reactive sites and loading space for efficient drug loading. The chemical reaction between catechol on the polydopamine surface and the thiol groups on the MMP-2 responsive peptides loads the peptide-drug dimers, thereby achieving responsive drug release on the carrier surface. Simultaneously, this invention utilizes the ability of polydopamine to scavenge reactive oxygen species (ROS), rapidly clearing local ROS and reducing acute damage caused by ischemic stroke.

The application discloses application of glycyrrhiza chalcone D in preparation of a drug for treating spontaneous cerebral hemorrhage and belongs to the technical field of biological medicine. The application provides application of glycyrrhiza chalcone D in preparation of a drug for treating and improving prognosis of spontaneous cerebral hemorrhage. Rat experiment results show that glycyrrhiza chalcone D can reduce hematoma of cerebral hemorrhage, reduce death of nerve cells after hemorrhage and reduce levels of inflammatory factors; cell experiment results show that glycyrrhiza chalcone D can be used as an inhibitor of ferroptosis and a COX2 inhibitor, improve ischemia and hypoxia injury of nerve cells after spontaneous cerebral hemorrhage and has a better effect than a commonly used ferroptosis inhibitor Fer-1. The application firstly reports that glycyrrhiza chalcone D is used for treating spontaneous cerebral hemorrhage and improving secondary brain injury, provides a new scheme for treatment of spontaneous cerebral hemorrhage and has a good clinical drug application prospect.

This invention provides a method, device, terminal, and medium for assistive training in the rehabilitation of spasticity after brain injury. The method includes: acquiring surface electromyography (EMG) signals and the start time of postural transition; obtaining average amplitude, maximum voluntary contraction amplitude, left-right symmetry index, stability index, and pre-activation time; obtaining a core muscle group function score based on the calculated average amplitude, maximum voluntary contraction amplitude, left-right symmetry index, stability index, and pre-activation time; determining the patient's training position, training goals, training mode, initial treatment parameters, and treatment optimization goals; guiding the patient in adaptive rehabilitation training, collecting surface EMG signals of the patient's core muscle groups in real time, dynamically adjusting stimulation parameters through an adaptive prediction model and the surface EMG signals, and completing the assistive rehabilitation training for spasticity after brain injury after the adaptive prediction model converges. This reduces reliance on the therapist's subjective experience and achieves precise rehabilitation training.

This invention belongs to the field of medicine, specifically relating to a nanomedicine targeting the central cortex for the treatment of brain injury and its application. The nanomedicine comprises a liposome shell formed of lipid material, and internally loaded with small interfering RNA, nucleic acid transfection-promoting materials, and anti-inflammatory drugs; the lipid material includes phospholipid materials and lipid excipients. The outer layer of the nanomedicine is modified with positively charged blood-brain barrier permeable material vascular endothelial growth factor (VEGF) through electrostatic adsorption. This invention utilizes the central targeting properties of lipid nanoparticles and VEGF to achieve highly efficient targeted delivery of the nanomedicine to the cerebral cortex region, delivering a series of repair-promoting drug components to the highly vulnerable cerebral cortex region, thereby improving the treatment effect of brain injury. This invention also relates to the preparation method and uses of this nanomedicine.

The present application provides the use of aucubin or the combination of aucubin and ACA in the preparation of a medicament for treating ischemic brain injury, in particular acute cerebral ischemia-reperfusion injury. The present application first discovers that aucubin or the combination of aucubin and ACA can increase the blood flow of the ischemic side after ischemic brain injury in mice; significantly reduce the cerebral infarction volume; improve the cognitive and motor function of mice after ischemic brain injury; reduce the degree of injury caused by cerebral ischemia, significantly improve the degree of neuronal necrosis of brain tissue after ischemia; significantly increase the survival rate of HT22 cells after oxygen-glucose deprivation and reperfusion injury, reduce intracellular Ca 2+ fluorescence intensity, and inhibit cell apoptosis.

A method for predicting the degree of disability of a multiple sclerosis patient, according to exemplary embodiments of the present invention, may comprise the steps of: obtaining information about a brain lesion area of the multiple sclerosis patient; mapping the brain lesion area onto a white matter streamline map including a plurality of voxels and information about the number of white matter streamlines passing through each voxel, thereby identifying voxels in the brain lesion area in the white matter streamline map; obtaining the number of voxels in the brain lesion area and the number of white matter streamlines passing through each voxel in the brain lesion area; determining a white matter path index of the brain lesion area on the basis of the number of voxels in the brain lesion area and the number of white matter streamlines passing through each voxel in the brain lesion area; and predicting the degree of disability of the multiple sclerosis patient on the basis of the white matter path index of the brain lesion area by using a rule-based model or a trained artificial intelligence model.

The present invention relates to pharmaceutical compositions for oral administration of A3R agonist compounds. The compositions are designed to disintegrate or disperse rapidly to deliver an effective dose of the compound for treating, ameliorating, or promoting recovery from certain conditions of the brain, central nervous system (CNS), or cardiovascular system such as a brain injury, a neurodegenerative condition, or cardiac ischemia.

This invention discloses the application of a traditional Chinese medicine composition in the preparation of drugs, foods, or health products for the prevention and / or treatment of Alzheimer's disease and / or neuroinflammation and / or cognitive impairment. The traditional Chinese medicine composition includes Hovenia dulcis, mung bean, sea buckthorn or fresh sea buckthorn, tangerine peel, mulberry or fresh mulberry, turmeric, and hawthorn. It exhibits good preventive and therapeutic effects on Alzheimer's disease, improves neuroinflammation, and alleviates cognitive impairment. It can effectively avoid the toxic effects of acetaldehyde on the human body, achieve the prevention of drunkenness and rapid sobering up. It has good improvement effects on alcoholic liver damage, alcoholic gastric damage, alcoholic kidney damage, alcoholic brain damage, alcoholic cardiomyopathy, and alcohol-induced cognitive impairment. It also has the effects of protecting the cardiovascular and cerebrovascular systems, strengthening the spleen and stomach, and protecting the liver. It has the advantages of having a small number of medicinal ingredients, low cost, convenient administration, no obvious toxic side effects, and convenient daily carrying. It is suitable for timely administration by people who want to sober up and for preventive health care by the general population. Its market prospects are even broader.

This invention relates to the field of pharmaceutical technology, specifically to a perioperative neuroprotective anesthetic composition and its application for ischemic stroke. The composition comprises the active ingredient remimazolam or a pharmaceutically acceptable salt thereof, MCC950, TRO19622, levamisole or a pharmaceutically acceptable salt thereof, lipoic acid, and a pharmaceutically acceptable carrier, with each active ingredient formulated in a specific molar ratio. This composition combines stable and controllable anesthetic effects with multi-target synergistic neuroprotective effects, adapting to the entire perioperative anesthesia needs for ischemic stroke. Through upstream and downstream synergistic inhibition of mitochondrial damage and the NLRP3 pyroptosis pathway, dual regulation of perioperative sympathetic tone to stabilize cerebral perfusion, synergistic reduction of glutamate excitotoxicity, and enhancement of endogenous antioxidant defense, it comprehensively blocks the core links of perioperative ischemia-reperfusion brain injury, significantly reducing the risk of postoperative neurological deficits and cognitive impairment. It exhibits excellent circulatory and respiratory safety, rapid awakening without affecting early postoperative neurological function assessment.

During childbirth process, trauma to an infant can readily arise, ultimately resulting in fetal hypoxia, academia, and brain damage. Such unfavorable conditions can be prevented by measuring the fetus' blood-oxygen level and heart rate. Without a fetal pulse oximeters, blood oxygen level cannot be monitored non-invasively reliably, which reduces the chance for birth complications to be recognized in time. A noninvasive system to implement such goals and maximize the potential welfare of the fetus may include devices to measure oxygen saturation of hemoglobin (SpO2). Such a device may be an oxy probe that uses a trans-reflective method of SpO2 measurement where oxygen saturation data can be transmitted through wire, fiber optics, and or using a radio frequency link, fetal monitor data can be analyzed, compared to existing data base, and or transmitted via radio waves or internet.